Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Top advances in lung cancer, 2021.

Cancer - 1 Oct 2022

Mohindra Nisha A, Patel Jyoti D

Abstract excerpt

Despite a global pandemic that continued to inflict chaos and confusion on the world, resulting in fewer cancer screenings and delayed surgeries, remarkable lung cancer treatment advancements were made in 2021. From immunotherapy in the adjuvant setting to the approval of the first-in-class, highly selective inhibitor of KRAS G12C, these treatment advances have significant clinical impact in patients with lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35947027
DOI: 10.1002/cncr.34406
PMCID: PMC9886158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Top advances in lung cancer, 2021.PMID 35947027Read ↗

[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity Read ↗

Lung Cancer: Targeted Therapy in 2025Semantic proximity Read ↗

[Targeted therapies for non-small cell lung cancer : state of the art in 2021].Semantic proximity Read ↗

Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026.Semantic proximity Read ↗

Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancerSemantic proximity Read ↗

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity Read ↗

Progress in the knowledge on the transformation of lung adenocarcinoma to small-cell lung cancerSemantic proximity Read ↗

Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.Semantic proximity Read ↗

KRAS-targeted therapy in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.Semantic proximity Read ↗

Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.Semantic proximity Read ↗

2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant ClassificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.